- Market Capitalization, $K 603,031
- Shares Outstanding, K 41,417
- Annual Sales, $ 363,470 K
- Annual Income, $ -91,430 K
- 60-Month Beta 1.14
- Price/Sales 1.68
- Price/Cash Flow N/A
- Price/Book 5.68
|Period||Period Low||Period High||Performance|
| || |
+0.34 (+2.37%)since 10/28/22
| || |
-3.91 (-21.04%)since 08/29/22
| || |
-2.43 (-14.21%)since 11/26/21
Today, Komodo Health announced a collaboration with Intercept Pharmaceuticals (Nasdaq: ICPT), powering clinical research and new real-world evidence with Komodo’s platform. Intercept leveraged Komodo’s...
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
Investors are cheering the drugmaker's Q3 update.
Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept: Q3 Earnings Snapshot
Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.
Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.
Poor earnings and a business setback were costly for these companies.
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
|3rd Resistance Point||15.44|
|2nd Resistance Point||15.18|
|1st Resistance Point||14.87|
|1st Support Level||14.30|
|2nd Support Level||14.04|
|3rd Support Level||13.73|